The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Xenobiotic-Metabolizing Enzymes Involved in Activation and Detoxification of Carcinogenic Polycyclic Aromatic Hydrocarbons
Abstract
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental carcinogens and metabolized by a variety of xenobiotic-metabolizing enzymes such as cytochrome P450 (P450 or CYP), epoxide hydrolase, glutathione transferase, UDP-glucuronosyltransferase, sulfotransferase, NAD(P)H quinone oxidoreductase 1, and aldo-keto reductase. These enzymes mainly participate in the conversion of PAHs to more polar and water-soluble metabolites, and the resultant metabolites are readily excreted from the body. However, during the course of metabolism, a variety of unstable and reactive intermediates of PAHs are formed, and these metabolites attack DNA, causing cell toxicity and transformation. P450s and epoxide hydrolase convert PAHs to proximate carcinogenic metabolites, PAH-diols, and these products are further metabolized by P450s to ultimate carcinogenic metabolites, PAH diol-epoxides, or by aldo-keto reductase to reactive PAH o-quinones. PAHs are also activated by P450 and peroxidases to reactive radical cations that bind covalently to DNA. The oxygenated and reactive metabolites of PAHs are usually converted to more polar and detoxified products by phase II enzymes. Inter-individual differences exist in levels of expression and catalytic activities of a variety of enzymes that activate and/or detoxify PAHs in various organs of humans and these phenomena are thought to be critical in understanding the basis of individual differences in response to PAHs. Factors affecting such variations include induction and inhibition of enzymes by diverse chemicals and, more importantly, genetic polymorphisms of enzymes in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935
Hayes, J. D., Flanagan, J. U., & Jowsey, I. R. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095857 · Cited by 3,544
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Self-citationConney, A. H. (1982) · PubMed · Cited by 1,557
Nebert, D. W., Dalton, T. P., Okey, A. B., & Gonzalez, F. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400004200 · Cited by 1,182
Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes
Guengerich, F. P., & Shimada, T. (1991) · Chemical Research in Toxicology · doi:10.1021/tx00022a001 · Cited by 1,000
Self-citationActivation of chemically diverse procarcinogens by human cytochrome P-450 1B1.
Shimada, T., Hayes, C. L., Yamazaki, H., Amin, S., Hecht, S. S., Guengerich, F. P., & Sutter, T. R. (1996) · PubMed · Cited by 895
Self-citationMetabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: A review
Xue, W., & Warshawsky, D. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.11.006 · Cited by 895
Glutathione-S-transferase family of enzymes
Strange, R. C., Spiteri, M. A., Ramachandran, S., & Fryer, A. A. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00206-8 · Cited by 831
Ding, X., & Kaminsky, L. S. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140251 · Cited by 822
Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily
Mackenzie, P. I., Walter Bock, K., Burchell, B., Guillemette, C., Ikushiro, S.-I., Iyanagi, T., Miners, J. O., Owens, I. S., & Nebert, D. W. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000173483.13689.56 · Cited by 821
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Shimada, T., & Fujii‐Kuriyama, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03162.x · Cited by 804
Self-citationFunctional role of AhR in the expression of toxic effects by TCDD
Mimura, J., & Fujii-Kuriyama, Y. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00485-3 · Cited by 746
Human Sulfotransferases and Their Role in Chemical Metabolism
Gamage, N., Barnett, A., Hempel, N., Duggleby, R. G., Windmill, K. F., Martin, J. L., & McManus, M. E. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj061 · Cited by 703
Stoilov, I. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.4.641 · Cited by 647
Bartsch, H., Nair, U., Risch, A., Rojas, M., Wikman, H., & Alexandrov, K. (2000) · PubMed · Cited by 627
Identification of a novel mechanism of regulation of Ah (dioxin) receptor function
Mimura, J., Ema, M., Sogawa, K., & Fujii-Kuriyama, Y. (1999) · Genes & Development · doi:10.1101/gad.13.1.20 · Cited by 585
The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., Shenfleld, G. M., Miners, J. O., Birkett, D. J., & Goldstein, J. A. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00007 · Cited by 582
Tumor-specific expression of cytochrome P450 CYP1B1.
Murray, G. I., Taylor, M. C., McFadyen, M. C. E., McKay, J., Greenlee, W. F., Burke, M. D., & Melvin, W. T. (1997) · PubMed · Cited by 532
Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis.
Pelkonen, O., & Nebert, D. W. (1982) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00051-1 · Cited by 512
Sutter, T. R., Tang, Y. M., Hayes, C. L., Wo, Y. Y., Jabs, E. W., Li, X., Yin, H., Cody, C. W., & Greenlee, W. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36803-5 · Cited by 508
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F., & Korzekwa, K. R. (1994) · Pharmacogenetics · doi:10.1097/00008571-199402000-00005 · Cited by 485
EPOXIDE HYDROLASES: Mechanisms, Inhibitor Designs, and Biological Roles
Morisseau, C., & Hammock, B. D. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095920 · Cited by 479
Buters, J. T. M., Sakai, S., Richter, T., Pineau, T., Alexander, D. L., Savas, U., Doehmer, J., Ward, J. M., Jefcoate, C. R., & Gonzalez, F. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.1977 · Cited by 383
OKEY, A., RIDDICK, D., & HARPER, P. (1994) · Toxicology Letters · doi:10.1016/0378-4274(94)90139-2 · Cited by 380
Potter, G. A., Patterson, L. H., Wanogho, E., Perry, P. J., Butler, P. C., Ijaz, T., Ruparelia, K. C., Lamb, J. H., Farmer, P. B., Stanley, L. A., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600197 · Cited by 380
Purification and characterization of hepatic microsomal cytochrome P-450
Ryan, D. E., & Levin, W. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90029-2 · Cited by 377
Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R. J., Mohrenweiser, H. W., & Goldstein, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29199-0 · Cited by 357
POLAND, A., & GLOVER, E. (1977) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12455-3 · Cited by 351
Cloning and expression of a human Ah receptor cDNA.
Dolwick, K. M., Schmidt, J. V., Carver, L. A., Swanson, H. I., & Bradfield, C. A. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13282-3 · Cited by 348
Nakajima, M., Yokoi, T., Mizutani, M., Kinoshitah, M., Funayama, M., & Kamataki, T. (1999) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022352 · Cited by 346
Targets for Dioxin: Genes for Plasminogen Activator Inhibitor-2 and Interleukin-1β
Sutter, T. R., Guzman, K., Dold, K. M., & Greenlee, W. F. (1991) · Science · doi:10.1126/science.1925598 · Cited by 337
Regulation, Function, and Tissue-Specific Expression of Cytochrome P450 CYP1B1
Murray, G. I., Melvin, W. T., Greenlee, W. F., & Burke, M. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.297 · Cited by 336
Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors.
Ema, M., Ohe, N., Suzuki, M., Mimura, J., Sogawa, K., Ikawa, S., & Fujii-Kuriyama, Y. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46990-6 · Cited by 329
Distlerath, L. M., Reilly, P. E., Martin, M. V., Davis, G. G., Wilkinson, G. R., & Guengerich, F. P. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39456-5 · Cited by 319
Uno, S., Dalton, T. P., Derkenne, S., Curran, C. P., Miller, M. L., Shertzer, H. G., & Nebert, D. W. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.5.1225 · Cited by 316
The aldo-keto reductase superfamily homepage
Hyndman, D., Bauman, D. R., Heredia, V. V., & Penning, T. M. (2003) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00193-x · Cited by 314
Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells
Spink, D. (1998) · Carcinogenesis · doi:10.1093/carcin/19.2.291 · Cited by 308
Raftogianis, R. B., Wood, T. C., Otterness, D. M., Van Loon, J. A., & Weinshilboum, R. M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7466 · Cited by 305
Analysis of the four alleles of the murine aryl hydrocarbon receptor
Poland, A., Palen, D., & Glover, E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09833-5 · Cited by 303
Genetic Mechanisms Controlling the Induction of Polysubstrate Monooxygenase (P-450) Activities
Nebert, D. W., Eisen, H. J., Negishi, M., Lang, M. A., Hjelmeland, L. M., & Okey, A. B. (1981) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.21.040181.002243 · Cited by 295
Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes
Fujii-Kuriyama, Y., & Mimura, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.162 · Cited by 290
Shimada, T., Iwasaki, M., Martin, M. V., & Guengerich, F. P. (1989) · PubMed · Cited by 265
Self-citationChoudhary, D., Jansson, I., Stoilov, I., Sarfarazi, M., & Schenkman, J. B. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2005.02.001 · Cited by 261
Shimada, T., Oda, Y., Gillam, E. M. J., Guengerich, F. P., & Inoue, K. (2001) · PubMed · Cited by 251
Self-citationHaining, R. L., Hunter, A. P., Veronese, M. E., Trager, W. F., & Rettie, A. E. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0414 · Cited by 249
Dickmann, L. J., Rettie, A. E., Kneller, M. B., Kim, R. B., Wood, A. J. J., Stein, C. M., Wilkinson, G. R., & Schwarz, U. I. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23142-4 · Cited by 249
Genetic expression of aryl hydrocarbon hydroxylase activity in the mouse
Nebert, D. W., Robinson, J. R., Niwa, A., Kumari, K., & Poland, A. P. (1975) · Journal of Cellular Physiology · doi:10.1002/jcp.1040850407 · Cited by 247
NAD(P)H:Quinone Oxidoreductase 1 (NQO1, DT-Diaphorase), Functions and Pharmacogenetics
Ross, D., & Siegel, D. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)82008-1 · Cited by 245
Spink, D. C., Eugster, H.-P., Lincoln, D. W., Schuetz, J. D., Schuetz, E. G., Johnson, J. A., Kaminsky, L. S., & Gierthy, J. F. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90404-k · Cited by 244
Resveratrol Is a Selective Human Cytochrome P450 1A1 Inhibitor
Chun, Y. J., Kim, M. Y., & Guengerich, F. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1152 · Cited by 243
Kapitulnik, J., Wislocki, P. G., Levin, W., et al. (1978) · PubMed · Cited by 240
Shimada, T., Yun, C. H., Yamazaki, H., Gautier, J. C., Beaune, P. H., & Guengerich, F. P. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09132-1 · Cited by 235
Self-citationShimada, T. (2002) · Carcinogenesis · doi:10.1093/carcin/23.7.1199 · Cited by 231
Self-citationIsolation and Characterization of the Human Cytochrome P450 CYP1B1 Gene
Tang, Y. M., Wo, Y.-Y. P., Stewart, J., Hawkins, A. L., Griffin, C. A., Sutter, T. R., & Greenlee, W. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28324 · Cited by 229
Uno, S., Dalton, T. P., Dragin, N., Curran, C. P., Derkenne, S., Miller, M. L., Shertzer, H. G., Gonzalez, F. J., & Nebert, D. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.021501 · Cited by 227
Selectivity of Polycyclic Inhibitors for Human Cytochrome P450s 1A1, 1A2, and 1B1
Shimada, T., Yamazaki, H., Foroozesh, M., Hopkins, N. E., Alworth, W. L., & Guengerich, F. P. (1998) · Chemical Research in Toxicology · doi:10.1021/tx980090+ · Cited by 223
Self-citationShimada, T., Mv, M., Pruess-Schwartz, D., Marnett, L. J., & Guengerich, F. P. (1989) · PubMed · Cited by 222
Self-citationBailey, L. R., Roodi, N., Dupont, W. D., & Parl, F. F. (1998) · PubMed · Cited by 220
Tobacco smoke carcinogens and breast cancer
Hecht, S. S. (2002) · Environmental and Molecular Mutagenesis · doi:10.1002/em.10071 · Cited by 215
THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS*
WRIGHTON, S. A., SCHUETZ, E. G., THUMMEL, K. E., SHEN, D. D., KORZEKWA, K. R., & WATKINS, P. B. (2000) · Drug Metabolism Reviews · doi:10.1081/dmr-100102338 · Cited by 213
Liehr, J. G., Ricci, M. J., Jefcoate, C. R., Hannigan, E. V., Hokanson, J. A., & Zhu, B. T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9220 · Cited by 208
Hakkola, J. (1997) · Carcinogenesis · doi:10.1093/carcin/18.2.391 · Cited by 205
Guillemette, C., Millikan, R. C., Newman, B. M., & Housman, D. E. (2000) · PubMed · Cited by 204
Targeted Disruption of the Microsomal Epoxide Hydrolase Gene
Miyata, M., Kudo, G., Lee, Y.-H., Fernandez-Salguero, P., Kimura, S., Gonzalez, F. J., Yang, T. J., & Gelboin, H. V. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23963 · Cited by 199
Human phenol sulfotransferases SULT1A2 and SULT1A1
Raftogianis, R. B., Wood, T. C., & Weinshilboum, R. M. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00145-8 · Cited by 197
Joseph, P., & Jaiswal, A. K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8413 · Cited by 192
Takahashi, H., Wilkinson, G. R., Caraco, Y., Muszkat, M., Kim, R. B., Kashima, T., Kimura, S., & Echizen, H. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.26a · Cited by 190
Pharmacogenetics of the major polymorphic metabolizing enzymes
Daly, A. K. (2003) · Fundamental & Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00119.x · Cited by 189
Shimada, T., & Guengerich, F. P. (2006) · Chemical Research in Toxicology · doi:10.1021/tx050291v · Cited by 185
Self-citationExpression of cytochromes P450 in human breast tissue and tumors.
Huang, Z., Fasco, M. J., Figge, H. L., Keyomarsi, K., & Kaminsky, L. S. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07451-3 · Cited by 184
Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., & Ingelman-Sundberg, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.659 · Cited by 181
Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer
Watanabe, J., Shimada, T., Gillam, E. M. J., Ikuta, T., Suemasu, K., Higashi, Y., Gotoh, O., & Kawajiri, K. (2000) · Pharmacogenetics · doi:10.1097/00008571-200002000-00004 · Cited by 176
Self-citationYamazaki, H., Inoue, K., Chiba, K., Ozawa, N., Kawai, T., Suzuki, Y., Goldstein, J. A., Guengerich, F. P., & Shimada, T. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00133-6 · Cited by 172
Self-citationPolymorphisms in the human AH receptor
Harper, P. A., Wong, J. M. Y., Lam, M. S. M., & Okey, A. B. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00071-6 · Cited by 168
Oxidation of xenobiotics by recombinant human cytochrome P450 1B1.
Shimada, T., Gillam, E. M. J., Sutter, T. R., Strickland, P. T., Guengerich, F. P., & Yamazaki, H. (1997) · PubMed · Cited by 166
Self-citationGenetic polymorphisms and lung cancer susceptibility: a review
Kiyohara, C., Otsu, A., Shirakawa, T., Fukuda, S., & Hopkin, J. M. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00107-1 · Cited by 165
Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse
Moriguchi, T., Motohashi, H., Hosoya, T., Nakajima, O., Takahashi, S., Ohsako, S., Aoki, Y., Nishimura, N., Tohyama, C., Fujii-Kuriyama, Y., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1037886100 · Cited by 164
Shimada, T., Gillam, E. M. J., Oda, Y., Tsumura, F., Sutter, T. R., Guengerich, F. P., & Inoue, K. (1999) · Chemical Research in Toxicology · doi:10.1021/tx990028s · Cited by 156
Self-citationZhang, Z., Fasco, M. J., Huang, L., Guengerich, F. P., & Kaminsky, L. S. (1996) · PubMed · Cited by 151
Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer.
Zheng, W., Xie, D., Jin, F., Cheng, J., Dai, Q., Wen, W., Shu, X., & Gao, Y. (2000) · PubMed · Cited by 151
Cytochrome P-450 1A1 Gene Polymorphisms and Risk of Breast Cancer: A HuGE Review
Masson, L. F., Sharp, L., Cotton, S. C., & Little, J. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi121 · Cited by 149
Chun, Y., Kim, S., Kim, D., Lee, S. K., & Guengerich, F. P. (2001) · PubMed · Cited by 148
Long, D. J., Waikel, R. L., Wang, X., Perlaky, L., Roop, D. R., & Jaiswal, A. (2000) · PubMed · Cited by 142
Cytochrome p450 1b1: A major p450 isoenzyme in human blood monocytes and macrophage subsets
Baron, J. M., Zwadlo-Klarwasser, G., Jugert, F., Hamann, W., Rübben, A., Mukhtar, H., & Merk, H. F. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00105-1 · Cited by 139
Shimada, T., Sugie, A., Shindo, M., Nakajima, T., Azuma, E., HASHIMOTO, M., & Inoue, K. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(02)00035-2 · Cited by 139
Self-citationJaiswal, A. K., Gonzalez, F. J., & Nebert, D. W. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.12.4503 · Cited by 137
Gelboin, H. V., Wiebel, F. J., & Diamond, L. C. (1970) · Science · doi:10.1126/science.170.3954.169 · Cited by 134
Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility.
Sunaga, N., Kohno, T., Yanagitani, N., Sugimura, H., Kunitoh, H., Tamura, T., 武井, 義., Tsuchiya, S., Saito, R., & Yokota, J. (2002) · PubMed · Cited by 134
Ntais, C., Polycarpou, A., & Ioannidis, J. P. A. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.176.14.1 · Cited by 123
Palackal, N. T., Burczynski, M. E., Harvey, R. G., & Penning, T. M. (2001) · Biochemistry · doi:10.1021/bi010872t · Cited by 120
Persson, I., Johansson, I., & Ingelman‐Sundberg, M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6051 · Cited by 118
Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J., & Kamataki, T. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00832.x · Cited by 118
Long, D. J., Waikel, R. L., Wang, X., Roop, D. R., & Jaiswal, A. K. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.15.1166 · Cited by 115
Glutathione S-transferases M1, T1, and P1 and Breast Cancer: A Pooled Analysis
Vogl, F. D., Taioli, E., Maugard, C. M., Zheng, W., Pinto, L. F. R., Ambrosone, C. B., Parl, F. F., Nedelcheva-Kristensen, V., Rebbeck, T. R., Brennan, P., et al. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.1473.13.9 · Cited by 110
Nebert, D. W., Ingelman‐Sundberg, M., & Daly, A. K. (1999) · Drug Metabolism Reviews · doi:10.1081/dmr-100101931 · Cited by 107
Kinoshita, N., & Gelboin, H. V. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.4.824 · Cited by 107
Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene.
Yun, C., Shimada, T., & Guengerich, F. P. (1992) · PubMed · Cited by 107
Self-citationIp, C. C. Y., Bayoumy, K. E., Upadhyaya, P., Ganther, H. E., Vadhanavikit, S., & Thompson, H. (1994) · Carcinogenesis · doi:10.1093/carcin/15.2.187 · Cited by 103
Wu, Z., Sohl, C. D., Shimada, T., & Guengerich, F. P. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023648 · Cited by 99
Self-citationKawajiri, K., & Fujii‐Kuriyama, Y. (1991) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1991.tb01800.x · Cited by 97
Kleiner, H. E., Vulimiri, S. V., Reed, M. J., Uberecken, A., & DiGiovanni, J. (2002) · Chemical Research in Toxicology · doi:10.1021/tx010151v · Cited by 93
Cytochrome P450 1B1 Determines Susceptibility to Dibenzo[a,l]pyrene-Induced Tumor Formation
Buters, J., Mahadevan, B., Quintanilla‐Martínez, L., Gonzalez, F. J., Greim, H. A., Baird, W. M., & Luch, A. (2002) · Chemical Research in Toxicology · doi:10.1021/tx020017q · Cited by 89
Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2
Pottenger, L. H., & Jefcoate, C. R. E. (1990) · Carcinogenesis · doi:10.1093/carcin/11.2.321 · Cited by 88
Jinno, H., Saeki, M., Saito, Y., Tanaka‐Kagawa, T., Hanioka, N., Sai, K., Kaniwa, N., Ando, M., Shirao, K., Minami, H., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051250 · Cited by 87
Murayama, N., Soyama, A., Saito, Y., Nakajima, Y., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Kimura, H., Goto, Y., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055798 · Cited by 86
Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk
Rylander‐Rudqvist, T. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg114 · Cited by 84
Bartsch, H., Rojas, M., Nair, U., Nair, J., & Alexandrov, K. (1999) · Cancer Detection and Prevention · doi:10.1046/j.1525-1500.1999.99055.x · Cited by 75
Shimada, T., Watanabe, J. A., Inoue, K., et al. (2001) · Xenobiotica · doi:10.1080/00498250110043490 · Cited by 74
Self-citationSulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study
Zheng, L., Wang, Y., Schabath, M. B., Grossman, H. B., & Wu, X. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.08.007 · Cited by 70
Inoue, K., Asao, T., & Shimada, T. (2000) · Xenobiotica · doi:10.1080/004982500237677 · Cited by 69
Self-citationLung cancer risk in African-Americans in relation to a racespecific CYP1a1 polymorphism
London, S. J., Daly, A. K., Fairbrother, K. S., Holmes, C., Carpenter, C. L., Navidi, W. C., & Idle, J. R. (1996) · Lung Cancer · doi:10.1016/0169-5002(96)87739-7 · Cited by 65
Identification of a novel splice‐site mutation in the CYP1A2 gene
Allorge, D., Chevalier, D., Lo‐Guidice, J., Cauffiez, C., Suard, F., Baumann, P., Eap, C. B., & Broly, F. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01858.x · Cited by 65
Jiang, H., Shen, Y.-M., Quinn, A. M., & Penning, T. M. (2005) · Chemical Research in Toxicology · doi:10.1021/tx0497245 · Cited by 65
Williams, J. A. (2001) · Carcinogenesis · doi:10.1093/carcin/22.2.209 · Cited by 64
Spencer, D. L., Masten, S. A., Lanier, K., Yang, X., Grassman, J. A., Miller, C. R., Sutter, T. R., Lucier, G. W., & Walker, N. J. (1999) · PubMed · Cited by 61
Lewis, S. J., Cherry, N., Niven, R. M., Barber, P. V., & Povey, A. C. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00243-4 · Cited by 57
Microsomal Epoxide Hydrolase Polymorphisms and Risk for Advanced Colorectal Adenoma
Huang, W., Chatterjee, N., Chanock, S. J., Dean, M. C., Yeager, M., Schoen, R. E., Hou, L.-F., Berndt, S. I., Yadavalli, S., Johnson, C. C., et al. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.152.14.1 · Cited by 51
Aldo-Keto Reductases and Formation of Polycyclic Aromatic Hydrocarbon o-Quinones
Penning, T. M. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)78003-9 · Cited by 46
Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene
Fujii‐Kuriyama, Y., Ema, M., Mimura, J., et al. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512001-00018 · Cited by 44
Shimada, T., Sugie, A., Yamada, T., Kawazoe, H., HASHIMOTO, M., Azuma, E., Nakajima, T., Inoue, K., & Oda, Y. (2003) · Xenobiotica · doi:10.1080/0049825031000140896 · Cited by 42
Self-citationGenetic Polymorphism of Human Cytochrome P450 Involved in Drug Metabolism
Nagata, K., & Yamazoe, Y. (2002) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.17.167 · Cited by 41
Niwa, Y., Hirose, K., Nakanishi, T., Nawa, A., Kuzuya, K., Tajima, K., & Hamajima, N. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.10.015 · Cited by 39
Zhang, L. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(03)00276-x · Cited by 24
Cited by
Huang, W.-Y., Cai, Y.-Z., & Zhang, Y. (2009) · Nutrition and Cancer · doi:10.1080/01635580903191585 · Cited by 1,009
Limón-Pacheco, J., & Gonsebatt, M. E. (2009) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2008.09.015 · Cited by 844
Microbial biodegradation of polyaromatic hydrocarbons
Peng, R.-H., Xiong, A.-S., Xue, Y., Fu, X.-Y., Gao, F., Zhao, W., Tian, Y.-S., & Yao, Q.-H. (2008) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2008.00127.x · Cited by 745
The Search for Endogenous Activators of the Aryl Hydrocarbon Receptor
Nguyen, L. P., & Bradfield, C. A. (2008) · Chemical Research in Toxicology · doi:10.1021/tx7001965 · Cited by 709
(EFSA), E. F. S. A. (2008) · EFSA Journal · doi:10.2903/j.efsa.2008.724 · Cited by 568
Metadata
- Authors
- Shimada, T.
- Venue
- Drug Metabolism and Pharmacokinetics
- Published
- 2006
- Volume
- 21
- Issue
- 4
- Pages
- 257-276
- ISSN
- 1347-4367 (ISSN-L)
- OpenAlex
- W2062467703
- Cited by
- 606
- References
- 126
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.